Beximco Pharmaceuticals (DHA:BXPHARMA) EV-to-Revenue : 1.91 (As of Apr. 26, 2024)

View and export this data going back to . Start your Free Trial

What is Beximco Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Beximco Pharmaceuticals's enterprise value is BDT58,275 Mil. Beximco Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was BDT30,492 Mil. Therefore, Beximco Pharmaceuticals's EV-to-Revenue for today is 1.91.

The historical rank and industry rank for Beximco Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

DHA:BXPHARMA' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.37 Med: 2.31 Max: 3.96
Current: 1.91

During the past 13 years, the highest EV-to-Revenue of Beximco Pharmaceuticals was 3.96. The lowest was 1.37. And the median was 2.31.

DHA:BXPHARMA's EV-to-Revenue is ranked better than
57.84% of 1027 companies
in the Drug Manufacturers industry
Industry Median: 2.29 vs DHA:BXPHARMA: 1.91

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-26), Beximco Pharmaceuticals's stock price is BDT116.60. Beximco Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was BDT68.35. Therefore, Beximco Pharmaceuticals's PS Ratio for today is 1.71.

Beximco Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Beximco Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beximco Pharmaceuticals EV-to-Revenue Chart

Beximco Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EV-to-Revenue

Get a 7-Day Free Trial

2.05

1.49

2.93

2.43

2.00

Beximco Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															2.53	2.13	2.10	2.00	2.47

Competitive Comparison of Beximco Pharmaceuticals's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beximco Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Beximco Pharmaceuticals's EV-to-Revenue falls into.

Beximco Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Beximco Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	58274.744	/	30492.133
	=	1.91

Beximco Pharmaceuticals's current Enterprise Value is BDT58,275 Mil.
Beximco Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT30,492 Mil.

Beximco Pharmaceuticals (DHA:BXPHARMA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Beximco Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	116.60	/	68.351
	=	1.71

Beximco Pharmaceuticals's share price for today is BDT116.60.
Beximco Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT68.35.

Beximco Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Beximco Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Beximco Pharmaceuticals (DHA:BXPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beximco Pharmaceuticals Ltd (DHA:BXPHARMA) » Definitions » EV-to-Revenue

Traded in Other Exchanges

BXP:UK R2WA:Germany

Address

19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205

Website

https://www.beximcopharma.com

Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from local sales.

Beximco Pharmaceuticals (DHA:BXPHARMA) Headlines

No Headlines